CD27 Ligand

CD27 Ligand

CD27 Ligand Molekülinformation

Molecule Name
CD70 antigen
Molekülalias
CD70,CD27LG,TNFSF7,TNFSF7G,CD27L
Drug Development Progress
Anzahl der klinischen Arzneimittel37
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
CD70 antigen,Surface Antigen CD70,LPFS3,CD27L,Tumor necrosis factor ligand superfamily member 7,CD27LG,CD27-L,CD70,CD70 Molecule,TNFSF7,Tumor Necrosis Factor (Ligand) Superfamily, Member 7,Tumor Necrosis Factor Ligand 8A,Ki-24 Antigen,TNLG8A,CD27 Ligand
Molekülhintergrund
Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

CD27 Ligand Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
CD70 VHH - 01LeadMonoclonalNanobodyHematological MalignancyNon-hodgkin lymphoma
Projektname
CD70 VHH - 01
Projektphase
Lead
Molekültyp
Monoclonal
Molekülquelle
Nanobody
Krankheitsgebiet
Hematological Malignancy
Indikationen
Non-hodgkin lymphoma